Abstract
The pharmacokinetics of piretanide, a new loop diuretic, were studied in four patients with GFR 4.7-14.8 ml/min. An oral dose of piretanide 18 mg was given at 08.00 h in two patients and at 08.00 h and 14.00 h in two. Blood samples were drawn after 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h. Serum concentrations of piretanide were estimated by radioimmunoassay. The peak serum concentration of piretanide (1-2 h after drug administration) was 510-880 ng/ml, independent of renal function. Elimination half life (t1/2) was 1.2-4.1 h, area under the curves (AUC(0,24)) 1.63-2.44 micrograms ml-1 h, volume of distribution (Vz) 0.30--0.741#kg, total plasma clearance (CL) 122.8-184.0 ml/min and renal clearance (CLR) 1.5-5.2 ml/min. The clinical effects of oral treatment with piretanide 18 mg twice daily were compared with bumetanide 3 mg twice daily in eight patients with renal failure (GFR 2.2-24.5 ml/min). Both drugs equally increased the 24 h output of urine (delta V), sodium (delta UNaV), chloride (delta UC1V), potassium (delta UKV) and calcium (delta UCaV). Fractional excretion of sodium (ENa%) was doubled by piretanide in patients with GFR less than 8 ml/min while a five fold increase was found in patients with GFR greater than 8 ml/min. The onset of effect was the same for both drugs, but the duration exceeded 6 h only for piretanide. Both drugs were most effective on the first of two consecutive treatment days. Delta UC1V was always greater than delta UNaV and urinary phosphate excretion was unchanged, as expected of a loop diuretic without significant proximal effects. Metabolic or clinical side effects were not noticed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berg K. J., Tromsdal A., Wideroe T. E. Diuretic action of bumetanide in advanced chronic renal insufficiency. Eur J Clin Pharmacol. 1976 Feb 6;9(4):265–275. doi: 10.1007/BF00561659. [DOI] [PubMed] [Google Scholar]
- Brazier J. L., Pozet N., Faucon G., Traeger J., Hadj-Haissa A. Kinetics of a high dose of piretanide in renal failure. Eur J Clin Pharmacol. 1982;21(4):307–310. doi: 10.1007/BF00637618. [DOI] [PubMed] [Google Scholar]
- Hadj Aissa A., Pozet N., Labeeuw M., Pellet M., Traeger J. Acute effect of high dose (48 mg) of piretanide in advanced renal insufficiency. Br J Clin Pharmacol. 1981 Jan;11(1):63–68. doi: 10.1111/j.1365-2125.1981.tb01103.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huang C. M., Atkinson A. J., Jr, Levin M., Levin N. W., Quintanilla A. Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther. 1974 Oct;16(4):659–666. doi: 10.1002/cpt1974164659. [DOI] [PubMed] [Google Scholar]
- Lawrence J. R., Ansari A. F., Elliott H. L., Sumner D. J., Brunton G. F., Whiting B., Whitesmith R. Kinetic and dynamic comparison of piretanide and furosemide. Clin Pharmacol Ther. 1978 May;23(5):558–565. doi: 10.1002/cpt1978235558. [DOI] [PubMed] [Google Scholar]
- Marone C., Reubi F. C. Effects of a new diuretic (piretanide) compared with furosemide on renal diluting and concentrating mechanisms in patients with the nephrotic syndrome. Eur J Clin Pharmacol. 1980;17(3):165–171. doi: 10.1007/BF00561895. [DOI] [PubMed] [Google Scholar]
- Odlind B. Relation between renal tubular secretion and effects of five loop diuretics. J Pharmacol Exp Ther. 1979 Oct;211(1):238–244. [PubMed] [Google Scholar]
- Pozet N., Hadj-Aissa A., Pellet M., Traeger J. Activity of a new high efficiency diuretic in man: piretanide (HOE 118). Br J Clin Pharmacol. 1980 Jun;9(6):577–583. doi: 10.1111/j.1365-2125.1980.tb01083.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roberts C. J., Homeida M., Roberts F., Bogie W. Effects of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects. Br J Clin Pharmacol. 1978 Aug;6(2):129–133. doi: 10.1111/j.1365-2125.1978.tb00837.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Teredesai P., Puschett J. B. Acute effects of piretanide in normal subjects. Clin Pharmacol Ther. 1979 Mar;25(3):331–339. doi: 10.1002/cpt1979253331. [DOI] [PubMed] [Google Scholar]